NVONOVO NORDISK A SSEC EDGAR
Use with Claude or ChatGPT

NOVO NORDISK A S (NVO) Overview

Healthcare • NYSE • CIK 0000353278

Loading...

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Market Cap
—
P/E (TTM)
—
Rev Growth (FY2025)
+6.4%
Net Margin (FY2025)
33.1%
FCF Yield (TTM)
—
FCF Margin (FY2025)
9.4%
Figures as of December 31, 2025
Data coverage notes

Showing annual figures as of December 31, 2025 (11 months old). This filer reports interim results in 6-K filings we do not yet process; trailing-twelve-month metrics are unavailable.

FPI filer (20-F or 40-F). Annual and balance-sheet coverage is strong; quarterly and TTM metrics are usually absent because most foreign private issuers do not tag their interim 6-K financials in XBRL. Valuation metrics (market cap, P/E, EV multiples, yields) are withheld by design, not missing: the US listing trades as depositary shares whose ratio to the ordinary share count is unverified. Revenue, earnings, margins and the cash-flow statement are unaffected.

Filings

Primary-source SEC disclosures, read end-to-end. SEC figures cite the filing they come from.

6-KNov 20262026-11-09source
6-KNov 20262026-11-05source
6-KNov 20262026-11-04source
6-KNov 20262026-11-03source
6-KOct 20262026-10-26source
What your agent reads

Investor Relations

www.novonordisk.com/investors/financial-results.html

Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.

Company-published, not SEC-audited

Earnings

Q3
12 days ago
6-K release
Revenue
—
Net Income
—
EPS
—
Withheld (eps basic, eps diluted, net income, operating income, revenue): Withheld: this company reports in DKK, and MetricDuck's earnings-release extraction does not yet record the currency of each extracted figure — so this value cannot be served as a dollar amount, and cannot be relabelled without guessing which column it came from. Percentages, operating metrics and the filing link are unaffected. Read the figure in the linked filing.
Earnings call — not catalogued
Most recent quarterly earnings snapshot

Filing Changes

340B Drug Pricing Program Riskhigh (USD 4.2B revenue constrained as provision for...→low (HRSA dismissed ADR petition January 20, 2026; USD...
US GLP-1 and Insulin Net Pricesmedium (US payer rebate pressure increasing in insulin...→medium (average net prices after rebates for full Novo...
GLP-1 Volume Market Sharemedium (competitive pressure emerging in both obesity...→medium (volume market share lost in GLP-1 for both...
Akero Therapeutics Acquisitionno MASH clinical-stage asset in pipeline→acquired Akero Therapeutics at $54 per share (Phase 3...
Illicit GLP-1 Compoundingmedium (GLP-1 drug shortage permitting compounding...→medium (GLP-1 shortage resolved but illicit compounding...
20-F FY 2025 vs 20-F FY 2024

Cash Flow Health

Free Cash Flow0/8 positive
TTM–
FCF Margin
TTM–
Sector: 3.0%
OCF Margin
FY202538.5%
OCF/NI–
CapEx Coverage
FY20252.0x
FCF Yield–
FCF Growth (3Y)–
Cash Conversion Cycle
–
Factsheet →
Cash flow trends & capital efficiency

Capital Allocation

Total Shareholder Yield
TTM—
Dividend & Payout Metrics
Dividend Yield (TTM)—
Buyback data not disclosed in this company's filings.
Shows how management rewards shareholders

Valuation Metrics

Price-to-EarningsTTM
–
Valuation Lenses
Earnings
–
vs – sector
Cash Flow
–
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: –
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap–
EV–

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Multi-angle valuation analysis with sector context

Margins & Efficiency

Profitability Cascade
Gross
81.0%
Operating
41.3%
Net
33.1%
Margins Unknown
Return on Invested Capital
—
P25MedianP75
(med: -7.7%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
—
Asset Turnover
0.61x
Leverage (1+D/E)
1.67x
D/E: 0.67x
Asset & CapEx Efficiency
Margin trends, ROIC, and capital efficiency

Balance Sheet & Solvency

D/E 0.67x
Net Debt / EBITDA
–Net Debt: $104.49B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.67x
Balance sheet risk & solvency analysis

Related Research

1 related post